Clinical Focus Targeting mitochondrial diseases and inflammatory conditions with first-in-class small molecules offers a niche for partnerships with specialty pharma and contract research organizations focusing on rare diseases and cardiovascular/ophthalmic indications.

Strategic Financing Recent grant funding and past multi-million financings indicate strong investor validation and potential for co-development or licensing discussions to accelerate OMT-28 and related compounds, appealing to strategic investors and pharma buyers.

Early Clinical Stage OMT-28 is in Phase 2a, presenting opportunities for clinical collaborators, investigator sites, and CROs with mitochondrial and metabolic disease expertise to support trial execution, outcomes research, and biomarker development.

Global Bidirectional Berlin-based biotech with international financing and collaboration history can attract European and US partners for co-development, manufacturing partnerships, and potential out-licensing of downstream assets.

Key Thought Leaders Board and leadership hires in science and business development signal readiness for strategic alliances; engage through executive-level outreach to explore licensing, commercialization rights, or joint ventures in cardiovascular and ophthalmic spaces.